Autoimmune disease Archives

News and Trends 30 Sep 2022

Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One

This week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored […]

September 30, 2022

News and Trends 19 Sep 2022

Cyxone receives approval for phase 2b rheumatoid arthritis study

Swedish biotech company Cyxone has received approval from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is […]

September 19, 2022 - 2 minutesmins - By Jim Cornall

PBC clinical trials: Gannex doses first patient

News and Trends 15 Sep 2022

Tridek-One brings in €16M to develop auto-immune diseases candidates

Tridek-One SAS, a French biotech startup specialized in the research and development of CD31 agonists to restore immune balance, has closed a €16 million ($16.1 million) new financing round. The financing was led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures, as well as historical investors AdBio partners and […]

September 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […]

September 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Aug 2022

World’s first CAR-T for treatment of inflammatory disorders of the central nervous system approved in China

China’s National Medical Products (NMPA) has approved an investigational new drug application from IASO Bio for the new extended indication of neuromyelitis optica spectrum disorder (NMOSD). Neuromyelitis optica spectrum disorders previously known as Devic disease or neuromyelitis optica are inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting […]

August 19, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Aug 2022

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […]

August 16, 2022 - 3 minutesmins - By Liza Laws

coronavirus COVID 19 Europe biotech lungs

News and Trends 21 Jul 2022

Additional funding for trial to study drug targeting lung immunity in elderly patients

Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Jul 2022

Financing round of $21M completed for drug to treat autoimmune diseases

The first-round of financing to the tune of $21 million (€20.6 million), for a drug to treat autoimmune disease, has been completed between Precision Autoimmune Therapeutics (PAT) and CASI Pharmaceuticals. PAT will pay CASI a $5 million (€4.9 million) equivalent as the first instalment of the upfront payment of the sub-license agreement. In May this […]

July 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

Funding doubled for company working on breakthrough auto-immune disease therapeutics

A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it has almost doubled its initial funding from two companies. The initial funding for Ermium Therapeutics of €6.3 million ($6.57 million) now stands at €12.3 million ($12.83 million) and has been supplied by Kurma Partners and Fountain Healthcare Partners. Ermium discovers […]

June 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jun 2022

Deal to advance treatment for autoimmune disease worth $97M

MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […]

June 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Jun 2022

ImmunOs Therapeutics raises $74M

ImmunOs Therapeutics AG, a biopharmaceutical company developing therapeutics for the treatment of cancer and autoimmune diseases, has announced the closing of an oversubscribed Series B financing round totaling $74M. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by other new investors Mission BioCapital, GL Capital, PEAK6 Strategic […]

June 7, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us